Sun Pharma’s allround growth can fuel stock

The outperformance was driven by a strong showing across all segments (except active ingredients) over the year-ago June quarter and over the preceding March quarter. Gains were made by the US specialty business, there was recovery in the branded generic portfolio in India besides some benefit from Covid-related drugs.

via Economictimes

No comments